- Home
- LAB vs JRI Comparison
LAB vs JRI Comparison
Compare LAB & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- JRI
- Stock Information
- Founded
- LAB 1999
- JRI 2012
- Country
- LAB United States
- JRI United States
- Employees
- LAB N/A
- JRI N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- JRI Finance Companies
- Sector
- LAB Industrials
- JRI Finance
- Exchange
- LAB Nasdaq
- JRI Nasdaq
- Market Cap
- LAB 473.2M
- JRI 385.5M
- IPO Year
- LAB 2011
- JRI N/A
- Fundamental
- Price
- LAB $1.35
- JRI $13.85
- Analyst Decision
- LAB Buy
- JRI
- Analyst Count
- LAB 2
- JRI 0
- Target Price
- LAB $2.50
- JRI N/A
- AVG Volume (30 Days)
- LAB 1.1M
- JRI 68.0K
- Earning Date
- LAB 10-29-2025
- JRI 01-01-0001
- Dividend Yield
- LAB N/A
- JRI 9.38%
- EPS Growth
- LAB N/A
- JRI N/A
- EPS
- LAB N/A
- JRI N/A
- Revenue
- LAB $172,271,000.00
- JRI N/A
- Revenue This Year
- LAB N/A
- JRI N/A
- Revenue Next Year
- LAB N/A
- JRI N/A
- P/E Ratio
- LAB N/A
- JRI N/A
- Revenue Growth
- LAB 76.33
- JRI N/A
- 52 Week Low
- LAB $0.92
- JRI $9.70
- 52 Week High
- LAB $2.32
- JRI $12.12
- Technical
- Relative Strength Index (RSI)
- LAB 55.30
- JRI 58.69
- Support Level
- LAB $1.27
- JRI $13.27
- Resistance Level
- LAB $1.41
- JRI $14.23
- Average True Range (ATR)
- LAB 0.08
- JRI 0.12
- MACD
- LAB 0.01
- JRI 0.02
- Stochastic Oscillator
- LAB 68.18
- JRI 56.82
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.